Advertisement

Urothelial Cancer | Specialty

The OncLive Urology condition center page is a comprehensive resource for clinical news and expert insights on urologic cancers, including prostate cancer, bladder cancer, testicular cancer, penile cancer, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

Roche to Withdraw US Indication for Atezolizumab in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma

November 29th 2022

Roche is voluntarily withdrawing the United States indication for atezolizumab for the treatment of adults with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy.

Dr. Schmid on the Rationale for the RACE IT Trial in Advanced Urothelial Carcinoma

November 15th 2022

Sebastian C. Schmid, MD, discusses the rationale for the phase 2 RACE IT trial in urothelial carcinoma.

Dr. Gupta on the Investigation of Enfortumab Vedotin With or Without Additional Therapy in mUC

November 14th 2022

Shilpa Gupta, MD, discusses the investigation of enfortumab vedotin with or without additional therapy in cisplatin-ineligible metastatic urothelial carcinoma.

Dr. Siefker-Radtke on Unmet Needs in Frontline Urothelial Cancer Treatment

November 14th 2022

Arlene O. Siefker-Radtke, MD, discusses key therapeutic developments aimed at addressing unmet needs in metastatic urothelial carcinoma treatment.

Dr. Siefker-Radtke on Erdafitinib in Urothelial Carcinoma

November 11th 2022

Arlene O. Siefker-Radtke, MD, discusses the use of erdafitinib in urothelial carcinoma.

Petrylak Previews Shift in Sequencing Paradigm in Urothelial Cancer

November 9th 2022

Daniel P. Petrylak, MD, highlights the use of checkpoint inhibitors, antibody-drug conjugates, and FGFR inhibitors in urothelial cancer and the current sequencing hurdles in the paradigm.

Dr. Gupta on Unmet Needs in Frontline Treatment of Metastatic Urothelial Cancer.

November 4th 2022

Shilpa Gupta, MD, discusses the unmet needs of patients with cisplatin-ineligible metastatic urothelial carcinoma.

Dr. Sonpavde on the Investigation of Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer

October 31st 2022

Guru P. Sonpavde, MD, discusses the investigation of enfortumab vedotin-ejfv with or without pembrolizumab in urothelial cancer.

Key Trial Data in Urothelial Carcinoma Treatment from ESMO 2022

October 26th 2022

Srikala Sridhar, MD, MSc, FRCPC, and Jeanny B. Aragon-Ching, MD, FACP, wrap up their review of updates in urothelial carcinoma by highlighting exciting data presented at ESMO 2022.

Metastatic Urothelial Carcinoma Treatment after Disease Progression on Avelumab

October 26th 2022

Key opinion leaders discuss the best treatment approaches for urothelial carcinoma after avelumab failure.

Dr. Aragon-Ching on the Future Implications of the JAVELIN Bladder 100 Trial in Urothelial Cancer

October 24th 2022

Jeanny B. Aragon-Ching, MD, FACP, discusses the future implications of the phase 3 JAVELIN Bladder 100 trial in urothelial cancer.

Mitomycin C Reduces the Number of Procedures Following NMIBC Recurrence

October 21st 2022

Chemoresection with mitomycin C, a nonsurgical treatment modality, significantly reduced the need for transurethral resection of bladder tumors or office biopsy and tumor fulguration following recurrence in patients with recurrent nonmuscle invasive bladder cancer.

Rogaratinib Is Noninferior to Chemo in Pretreated FGFR1/3 mRNA+ Locally Advanced or Metastatic Urothelial Carcinoma

October 19th 2022

Rogaratinib induced an objective response rate similar to that of chemotherapy in patients with FGFR1/3 mRNA–positive locally advanced or metastatic urothelial carcinoma who have received at least 1 prior platinum-containing chemotherapy.

Outcomes of the JAVELIN Bladder 100 Trial

October 19th 2022

Jeanny B. Aragon-Ching, MD, FACP, describes the outcomes of the JAVELIN Bladder 100 study that she presented at ESMO 2022.

Treatment Options for Frontline Metastatic Urothelial Carcinoma

October 19th 2022

Drs Aragon-Ching and Sridhar review the available treatment options for patients with frontline metastatic urothelial carcinoma and explain the design of an exciting clinical trial.

Dr. Gupta on the Investigation of Cabozantinib Plus Avelumab in Metastatic Urothelial Cancer

October 18th 2022

Shilpa Gupta, MD, discusses the addition of cabozantinib to avelumab in locally advanced or metastatic urothelial cancer.

An Influx of Data Expands Options, Improves Treatment for Bladder Cancer

October 18th 2022

The past decade has seen a change in the tide for patients with bladder cancer with the introduction of checkpoint blockade and molecular profiling.

Standards of Care Shift Toward Patient Specificities in Bladder and Prostate Cancers

October 13th 2022

Shilpa Gupta, MD, discussed potential therapies for patients with cisplatin-ineligible metastatic urothelial carcinoma, the benefits of sacituzumab govitecan and erdafitinib in later-line urothelial carcinoma, and treatment options for nonmetastatic castration-resistant prostate cancer.

Neoadjuvant Chemotherapy in Urothelial Carcinoma: The IMvigor010 Study

October 13th 2022

Dr Jeanny B. Aragon-Ching starts a conversation on negative trial data in the high-risk urothelial carcinoma treatment setting for neoadjuvant chemotherapy.

Neoadjuvant Chemotherapy in Urothelial Carcinoma: The CHECKMATE-274 Trial

October 12th 2022

Experts discuss trial data from CHECKMATE-274 on the use of neoadjuvant chemotherapy for high-risk urothelial carcinoma treatment.

Advertisement
Advertisement